A Pilot Study of Edrecolomab (Panorex, 17-1A Antibody) and Capecitabine in Patients with Advanced or Metastatic Adenocarcinoma

References

• Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishisuka H. Design of a novel fluoropyrimidine carbamate, which generates 5-fluroruracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998; 34((8))1274–1281
   PubMed Web of Science ®Google Scholar
• Blum J.L., Jones S.E., Budzar A.U., LoRusso P.M., Kuter I., Vogel C., Osterwalder B., Burger H.U., Brown C.S., Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999; 17((2))485–493
   PubMed Web of Science ®Google Scholar
• Van Custem E., Findlay M., Osterwalder B., Kocha W., Dalley D., Pazdur R., Cassidy J., Dirix L., Twelves C., Allman D., Seitz J.F., Scholmerich J., Burger H.U., Verweij J. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J. Clin. Oncol. 2000; 18((6))1337–1345
   PubMed Web of Science ®Google Scholar
• Cox J.V., Pazdur R., Thibault A., Maroun J., Weaver C., Jahn M.W., Harrison E., Griffin T. A Phase III trial of XELODA (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 1016
   Google Scholar
• Wenzel C., Schmidinger M.P., Locker G.J., Tomek S., Mader R.M., Zielinski C.C., Steger G.G. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy. Proc. Am. Soc. Clin. Oncol. 2000; 19: 1457
   Google Scholar
• Cartwright T. A Phase II trial of Xeloda (capectiabine) in advanced or metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 1026
   Google Scholar
• XELODA (capecitabine) product label. Roche Laboratories, Inc., 1998.
   Google Scholar
• Gottlinger H.G., Funke I., Johnson J.P., Gokel J.M., Reithmuller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution, and recognition by different monoclonal antibodies. Int. J. Cancer 1986; 38((1))47–53
   PubMed Web of Science ®Google Scholar
• Adkins J.C., Spencer C.M. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998; 56((4))627–628
   Google Scholar
• Frodin J.E., Lefvert A.K., Mellstedt H. Pharmacokinetics of the mouse monoclonal antibodies 17-1A in cancer patients receiving various treatment schedules. Cancer Res. 1990; 50((16))4866–4871
   PubMed Web of Science ®Google Scholar
• Herlyn D., Sears H., Iliopoulos D., Lubeck M., Douillard J.Y., Sindelar W., Tempero M., Mellstedt H., Maher M., Koprowski H. Anti-idiotype antibodies to monoclonal antibody CO17-1A. Hybridoma 1986; 5((Suppl. 1))S51–S58
   PubMedGoogle Scholar
• Riethmuller G., Schneider-Gladicke E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343((8907))1177–1183
   PubMed Web of Science ®Google Scholar
• Gruber R., van Haarlem L.J., Warnaar S.O., Holz E., Riethmuller G. The human anti-mouse immunoglobulin response and the anti-idiotype network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 2000; 60((7))1921–1926
   PubMed Web of Science ®Google Scholar
• Fagerberg J., Hjelm A.L., Ragnhammer P., Frodin J.E., Wigzell H., Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995; 55((9))1824–1827
   PubMed Web of Science ®Google Scholar
• Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Bruggisch P., Witte J. Monoclonal antibody therapy for resected Dukes' C colorectal carcinoma: seven year outcome of a multicenter randomized trial. J. Clin. Oncol. 1998; 16((5))1788–1794
   PubMed Web of Science ®Google Scholar
• Braun S., Hepp F., Kentenich C.R., Janni W., Pantel K., Riethmuller G., Willgeroth F., Sommer H.L. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin. Cancer Res. 1999; 52((9))701–704
   Google Scholar
• Dresemann G. Antibody treatment of Dukes C colon carcinoma with minimal residual disease. Proc. Am. Soc. Clin. Oncol. 2000; 19: 968
   Google Scholar
• Schilling E.M., Voigtmann R. Edrecolomab leads to reduction of 17-1A-positive disseminated breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 1859
   Google Scholar
• Fagerberg H., Hjelm A.L., Ragnhammer P., Frodin J.E., Wigzell H., Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995; 55((9))1824–1827
   PubMed Web of Science ®Google Scholar
• Frodin J.E., Harmenberg U., Biberfeld P., Christensson B., Lefvert A.K., Rieger A., Shetye J., Wahren B., Mellstedt H. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988; 7((4))309–321
   PubMed Web of Science ®Google Scholar
• Ragnhammer P., Fagerberg J., Frodin J.E., Hjelm A.L., Lindemalm C., Magnusson I., Masucci G., Mellstedt H. Effect of monoclonal antibody 17-1A and GM-CSR in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced. Int. J. Cancer 1993; 53((5))751–758
   PubMed Web of Science ®Google Scholar
• Sidelar W.F., Maher M.M., Herlyn D., Sears H.F., Steplewski Z., Koprowski H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma 1986; 5((Suppl. 1))S125–S132
   PubMedGoogle Scholar
• Tempero M.A., Sivinski C., Steplewski Z., Harvey E., Klassen L., Kay H.D. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J. Clin. Oncol. 1990; 8((12))2019–2026
   PubMed Web of Science ®Google Scholar
• Fields A.L.A., Nagy A., Schwartzberg L., Punt C.J.A., Barton J., Barber L., Colman J.R., Wissel P.S. Edrecolomab alone or in combination with 5-FU based chemotherapy in adjuvant treatment of stage III colon cancer: a safety review. Proc. Am. Soc. Clin. Oncol. 1999; 19: 1676
   Google Scholar
• Punt C.J., Nagy A., Douillard J., Figer A., Skovsgaard T., Monson J., Barone C., Jones D., Dethling J., Colman J. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc. Am. Soc. Clin. Oncol. 2001; 20: 487
   Google Scholar
• Slamon D., Leyland-Jones B., Shak S., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Baselga J., Norton L. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol. 1998; 17: 377
   Google Scholar
• Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., Jonas C., Klippenstein D., Dallaire B., Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999; 17((1))268–276
   PubMed Web of Science ®Google Scholar
• Link B.K., Grossbard M.L., Fisher R.I., Czuczman M., Gilman P., Lowe A.M., Vose J.M. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade NHL. Proc. Am. Soc. Clin. Oncol. 1998; 17: 7
   Google Scholar
• Coiffier B., Lepage E., Herbrecht R., Tilly H., Solal-Celigny P., Munck J.N., Bouabdallah R., Lederlin P., Sebban C., Morel P., Haioun C., Salles G., Molina T. Mabthera (rituximab) plus CHOP is superior to CHOP in elderly patients with diffuse large B cell lymphoma: interim results of a randomized GELA trial. Blood 2000; 96((Suppl. 1))950, 223a
   PubMedGoogle Scholar
• Mackean M., Planting A., Twelves C., Schellens J., Allman D., Osterwalder B., Reigner B., Griffin T., Kaye S., Verweij J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998; 16((9))2977–2985
   PubMed Web of Science ®Google Scholar
• LoBuglio A.F., Saleh M.N., Lee J., Khazaeli M.B., Carrano R., Holden H. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. Clinical aspects. J. Natl Cancer Inst. 1988; 80((12))932–936
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F.B., Rodrigues M.A., Sarris A.H., Pate O., Younes A., Lee M.S., Dang N.H., Romaguera J.E., Preti A.H., McAda N., Cabanillas F. Safety of fludarabine, Mitorantrone, and dexamethasone combined with otuximab in the treatment of stage IV indolent lymphoma. Semin. Oncol. 2000; 27((6 Suppl. 12))37–41
   Google Scholar